Edition:
United States

Neurocrine Biosciences Inc (NBIX.OQ)

NBIX.OQ on NASDAQ Stock Exchange Global Select Market

71.18USD
12:59pm EST
Change (% chg)

$-0.63 (-0.88%)
Prev Close
$71.81
Open
$71.14
Day's High
$71.76
Day's Low
$70.81
Volume
172,077
Avg. Vol
353,430
52-wk High
$75.87
52-wk Low
$37.37

Chart for

About

Neurocrine Biosciences, Inc. is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-re... (more)

Overall

Beta: 0.32
Market Cap(Mil.): $6,354.69
Shares Outstanding(Mil.): 88.49
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 189.97 15.54
EPS (TTM): -- -- --
ROI: -- -10.87 11.80
ROE: -- -36.85 15.75

BRIEF-Neurocrine Biosciences appoints Matt Abernethy as CFO

* Neurocrine Biosciences appoints Matt Abernethy as chief financial officer

Nov 20 2017

BRIEF-Neurocrine Biosciences reports Q3 loss per share $0.13

* Q3 earnings per share view $-0.49 -- Thomson Reuters I/B/E/S

Nov 01 2017

BRIEF-Neurocrine initiates Phase IIb clinical study of Ingrezza

* Neurocrine initiates phase IIb clinical study of once-daily Ingrezza in children and adolescents with Tourette syndrome

Oct 25 2017

BRIEF-Neurocrine granted FDA orphan drug designation for Valbenazine

* Neurocrine granted FDA orphan drug designation for valbenazine for the treatment of pediatric patients with Tourette syndrome Source text for Eikon: Further company coverage:

Oct 23 2017

BRIEF-Neurocrine announces FDA approval of 80 mg Ingrezza

* Neurocrine announces FDA approval of 80 mg Ingrezza® (valbenazine) capsules for the treatment of adults with tardive dyskinesia (TD)

Oct 05 2017

BRIEF-Perceptive Advisors reports 5.3 pct passive stake in Neurocrine Biosciences

* Perceptive Advisors LLC reports 5.3 percent passive stake in Neurocrine Biosciences Inc as of September 6, 2017 - SEC filing‍​ Source: (http://bit.ly/2wOUVQY) Further company coverage:

Sep 08 2017

BRIEF-Neurocrine Biosciences Q2 loss per share $0.68

* Q2 earnings per share view $-0.66 -- Thomson Reuters I/B/E/S

Aug 03 2017

BRIEF-Neurocrine Biosciences says PDUFA goal date is Oct. 14 for Ingrezza 80 mg capsules

* Neurocrine Biosciences Inc - has been advised that PDUFA goal date is october 14, 2017 for Ingrezza 80 mg capsules - sec filing Source text for Eikon: (http://bit.ly/2spiVra) Further company coverage:

Jul 05 2017

Earnings vs. Estimates